---
title: "Genome-wide genetic dataset generated for the Australian 45 and Up Study"
id: "medrxiv-17-a-genome-wide-genetic-data-resource-for-the-45-and-up-study"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-a-genome-wide-genetic-data-resource-for-the-45-and-up-study"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.20.26363524v1?rss=1"
published_at: "2026-09-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Genome-wide genetic dataset generated for the Australian 45 and Up Study
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-a-genome-wide-genetic-data-resource-for-the-45-and-up-study
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.20.26363524v1?rss=1)
- **Published At:** 2026-09-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study generated and validated a new **genome-wide genetic** data resource within the Australian **45 and Up Study**, a large population-based cohort recruited 2005–2009 with extensive longitudinal and linked health data. - In 2022–2023, 30,541 participants were invited: a random sub-cohort plus all individuals in the cohort with history of the four most common invasive cancers (breast, prostate, melanoma, colorectal). - DNA sample consent and non-consent were mapped to participant characteristics to document differences between those who provided samples and those who did not. - Low-coverage whole-genome sequencing (0.4–6.3×) plus imputation produced approximately 79 million variants for 7,408 individuals; 6,827 individuals' data passed stringent quality control. - Genotype concordance was high between duplicate samples (n=85) and when compared with dense genotyping arrays (n=188), supporting data reliability. - The majority of unrelated participants with high-quality data had inferred European genetic ancestry (6,631, 98%); 141 (2%) were inferred non-European or admixed ancestry. - As proof of concept, integration with linked health records enabled calculation of **polygenic risk scores (PGS)** for the four most common cancers; PGS performance was broadly consistent with prior studies. - Specific PGS findings included association of higher prostate cancer PGS with earlier age at diagnosis and no meaningful differences in cancer stage at diagnosis by PGS. - Data access is controlled by custodians (Sax Institute and NSW Ministry of Health); newly generated genomic data will be deposited to the European Genome-phenome Archive (EGA) upon publication. - Ethical approvals were obtained from the Human Research Ethics Committee of the University of New South Wales and the New South Wales Population and Health Services Research Ethics Committee; authors declared no competing interests. - Funders include the Medical Research Future Fund Genomic Health Futures Mission, the NHMRC, Cancer Institute NSW, and Cancer Council NSW.
## Clinical Analysis & Structured Key Points
A Genome-wide Genetic Data Resource for the 45 and Up Study | medRxiv Skip to main content A Genome-wide Genetic Data Resource for the 45 and Up Study Hamzeh Mesrian Tanha , David Goldsbury , Richard Parker , Natalie Garden , Erika de Guzman , Greer Dawson , Kerrin Bleicher , Alison Cowle , Martin McNamara , Anne E Cust , Nicholas G Martin , Julia Steinberg doi: https://doi.org/10.64898/2026.09.20.26363524 Hamzeh Mesrian Tanha 1 The Daffodil Centre, The University of Sydney and Cancer Council NSW, Sydney, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site David Goldsbury 1 The Daffodil Centre, The University of Sydney and Cancer Council NSW, Sydney, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Richard Parker 2 QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Natalie Garden 2 QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Erika de Guzman 3 Central Analytical Research Facility (CARF), Queensland University of Technology (QUT), Brisbane, QLD, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Greer Dawson 4 Sax Institute, Sydney, NSW, Australia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kerrin Bleicher 4 Sax Institute, Sydney, NSW, Australia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alison Cowle 4 Sax Institute, Sydney, NSW, Australia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Martin McNamara 4 Sax Institute, Sydney, NSW, Australia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anne E Cust 1 The Daffodil Centre, The University of Sydney and Cancer Council NSW, Sydney, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nicholas G Martin 2 QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Julia Steinberg 1 The Daffodil Centre, The University of Sydney and Cancer Council NSW, Sydney, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: julia.steinberg{at}sydney.edu.au Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Large population-based cohorts enable investigation of disease risk and precision prevention, but often lack genome-wide genetic data. We generated and validated new genomic data within the Australian 45 and Up Study, one of the largest Southern Hemisphere cohorts (recruited 2005-2009) with extensive longitudinal and linked health data. In 2022-2023, 30,541 participants were invited (random sub-cohort and all individuals with history of four most common invasive cancers: breast, prostate, melanoma, colorectal), with in-depth mapping of participants' characteristics for people who consented to provide a DNA sample and those who did not. Low-coverage whole-genome sequencing data (0.4-6.3x) followed by imputation yielded ~79 million variants for n=7,408 individuals; data for n=6,827 passed stringent quality control. Genotype concordance was high between duplicates (n=85) and with dense genotyping arrays (n=188). Most unrelated participants with high-quality data had inferred European genetic ancestry (n=6,631, 98%), with n=141 (2%) of inferred non-European or admixed ancestry. As proof-of-principle integration of new genomic data with extensive existing linked health records, polygenic risk scores (PGS) for four most common cancers showed predictive performance broadly consistent with previous studies, including association between PGS and earlier age at prostate cancer diagnosis, and no meaningful differences in cancer stage at diagnosis by PGS. This new resource has substantially enhanced the 45 and Up Study, supporting investigations of disease aetiology, risk stratification, and precision health in Australia and globally. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Human Research Ethics Committee of the University of New South Wales gave ethical approval for this work (HC210602). New South Wales Population and Health Services Research Ethics Committee gave ethical approval for this work (2019/ETH01746; HREC/14/CIPHS/54). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Study data are available from the data custodians (Sax Institute for the 45 and Up Study and genomic data; NSW Ministry of Health for NSW Cancer Registry and NSW Registry of Births, Death and Marriages) for approved research projects. However, direct provision of the data by the authors is not permitted by the relevant data custodians, as it would compromise participants' confidentiality and privacy. Data access enquiries can be made to the Sax Institute by email (45andUp.research{at}saxinstitute.org.au), or see https://www.saxinstitute.org.au/solutions/45-and-up-study/use-the-45-and-up-study for details. Upon publication, all newly generated genomic data will also be deposited to the European Genome-phenome Archive (EGA). Funder Information Declared Medical Research Future Fund (MRFF) – Genomic Health Futures Mission , 2007708 National Health and Medical Research Council (NHMRC) , 2008454 Cancer Institute NSW , 2022/CDF1154 Cancer Council NSW, https://ror.org/05gsbkp40 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 22, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following A Genome-wide Genetic Data Resource for the 45 and Up Study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share A Genome-wide Genetic Data Resource for the 45 and Up Study Hamzeh Mesrian Tanha , David Goldsbury , Richard Parker , Natalie Garden , Erika de Guzman , Greer Dawson , Kerrin Bleicher , Alison Cowle , Martin McNamara , Anne E Cust , Nicholas G Martin , Julia Steinberg medRxiv 2026.09.20.26363524; doi: https://doi.org/10.64898/2026.09.20.26363524 Share This Article: Copy Citation Tools A Genome-wide Genetic Data Resource for the 45 and Up Study Hamzeh Mesrian Tanha , David Goldsbury , Richard Parker , Natalie Garden , Erika de Guzman , Greer Dawson , Kerrin Bleicher , Alison Cowle , Martin McNamara , Anne E Cust , Nicholas G Martin , Julia Steinberg medRxiv 2026.09.20.26363524; doi: https://doi.org/10.64898/2026.09.20.26363524 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4835) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1634) Epidemiology (15982) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7070) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5070) Health Policy (1438) Health Systems and Quality Improvement (1776) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16313) Intensive Care and Critical Care Medicine (1177) Medical Education (673) Medical Ethics (155) Nephrology (727) Neurology (7308) Nursing (370) Nutrition (1087) Obstetrics and Gynecology (1245) Occupational and Environmental Health (1007) Oncology (3622) Ophthalmology (1058) Orthopedics (398) Otolaryngology (458) Pain Medicine (476) Palliative Medicine (140) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5923) Public and Global Health (9778) Radiology and Imaging (2437) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (582) Surgery (783) Toxicology (107) Transplantation (306) Urology (293)
## Related Clinical Research

- [Cancer type–specific chromatin regulator mutations linked to better survival after immune checkpoi](https://medichelpline.com/clinical-feed/medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies.md)
- [Moderna and Merck's mRNA Cancer Vaccine: Inside the Melanoma Trial Breakthrough](https://medichelpline.com/clinical-feed/stat-news-0-stat-inside-moderna-and-merck-s-cancer-vaccine-triumph.md)
- [Radiopharmaceuticals in Cancer: Promise of Targeted Therapy Meets New Safety Concerns](https://medichelpline.com/clinical-feed/stat-news-2-stat-the-promise-of-radiopharmaceuticals-smacks-into-safety-concerns.md)
- [Hormonal Management in Older Transgender and Gender Diverse Adults: Case-Based Considerations](https://medichelpline.com/clinical-feed/pubmed-42274359.md) (DOI: 10.1210/clinem/dgag231)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.